Top 25 Dermatological Drugs Manufacturers 2019

皮膚科用医薬品製造のトップ25社2019

◆タイトル:Top 25 Dermatological Drugs Manufacturers 2019
◆商品コード:VGN906172
◆調査・発行会社:visiongain
◆発行日:2019年4月
◆ページ数:176
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥358,967見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥398,867見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥664,867見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"皮膚科用医薬品製造のトップ25社2019"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、主要企業分析などの情報をお届けいたします。

Dermatological drugs market has been growing over the last decade. A combination of significant new market launches, and corporate activities has changed the outlook of the pharmaceutical industry towards this market. The dermatological drugs market in 2018 was reported to be US$ 26.23bn. Visiongain’s analysis of the market shows Humira, Stelara, Enbrel, Remicade, Otezla and Cosentyx among the top dermatological drugs driving the market at present.How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 176-page report you will receive 108 tables and 71 figures– all unavailable elsewhere.
The 176-page report provides clear detailed insight into the top 25 dermatological drugs manufacturers. Discover the key drivers and challenges affecting the market.
Report Scope
• Assessment of the leading companies in the global dermatological drugs market. The list below shows some of the companies that are discussed in the report:
• Abbvie Inc.
• Allergan plc
• Almirall S.A.
• Amgen
• Astellas
• Bayer
• Concert Pharmaceuticals
• Eli Lilly and Company
• Galderma
• GlaxoSmithkline plc (GSK)
• Johnson & Johnson (J&J)
• Leo Pharma A/S
• Lupin Ltd
• Mayne Pharma
• Other companies
• For each company, the report provides information and discussion on:
• Total revenue forecast to 2028
• Dermatology segment revenue forecast to 2028
• The leading dermatology drugs revenue forecast to 2028
• Drugs portfolio
• Recent developments
• The report provides revenue forecast to 2028 for the following dermatological drugs:
• Epiduo
• Differin
• Stelara
• Remicade
• Humira
• Valtrex
• Lamisil
• Bactroban
• Dermovate
• Zyvox
• Protopic
• Solodyn
• Ziana
• Taltz
• Cosentyx
• Aczone
• Cubicin
• Elocon
• Absorica /Epirus
• Enbrel
• Doryx
• Canesten
• Bepanthen/Bepanthol
• Key questions answered by this report:
• How is the Dermatological Drugs Manufacturers market evolving?
• What is driving and restraining the Dermatological Drugs Manufacturers market?
• What will be the main driver for the overall market to 2028?
• Will leading Dermatological Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
Visiongain’s study is intended for anyone requiring commercial analyses for the Top 25 Dermatological Drugs Manufacturers 2019. You find data, trends and predictions.
Buy our report today Top 25 Dermatological Drugs Manufacturers 2019: Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies.

【レポートの目次】

1. Report Overview
1.1 Why You Should Read This Report
1.2 How the Study Delivers
1.3 Main Questions Covered in the Analysis
1.4 Who is this Report For?
1.5 Methods of Research and Analysis
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation and Forecasting Methods
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Reports
1.8 About Visiongain

2. Leading Companies in the Dermatological Drugs Market 2019
2.1 Dermatological Drugs – A Rapidly Consolidating Market
2.2 Galderma (Nestle Skin Health S.A.)
2.2.1 Galderma (Nestle Skin Health S.A.): Total Revenue Forecast to 2028
2.2.2 Galderma (Nestle Skin Health S.A.): Dermatology Revenue Forecast to 2028
2.2.3 Galderma: Dermatological Drugs Portfolio, 2018
2.2.4 Global Leading Dermatological Drugs Galderma
2.2.4.1 Epiduo
2.2.4.1.1 Epiduo: Revenue Forecast to 2028
2.2.4.2 Differin
2.2.4.1.2 Differin: Revenue Forecast to 2028
2.2.5 Galderma: Recent Developments
2.2.5.1 Nestlé’s Acquisition of Galderma
2.2.5.2 Approval and Launch of Soolantra for Rosacea
2.2.5.3 FDA Approval of Restylane Lyft for Hands
2.2.5.4 Collaboration between Janssen’s and Galderma’s Nordic affiliates
2.3 Johnson & Johnson (J&J)
2.3.1 Johnson & Johnson: Total Revenue Forecast to 2028
2.3.2 Johnson & Johnson: Dermatology Revenue Forecast to 2028
2.3.3 Johnson & Johnson: Dermatological Drugs Portfolio, 2018
2.3.4 Global Leading Dermatological Drugs Johnson & Johnson
2.3.4.1 Stelara
2.3.4.1.1 Stelara: Revenue Forecast to 2028
2.3.4.2 Remicade
2.3.4.2.1 Remicade: Revenue Forecast to 2028
2.3.5 Johnson & Johnson: Recent Developments
2.3.5.1 U.S. FDA Approval of Tremfya (Guselkumab)
2.3.5.2 New TREMFYA (GUSELKUMAB) Data Demonstrates Long–Term Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
2.3.5.3 Extended Indication U.S. FDA Approval of STELARA (ustekinumab)
2.4 AbbVie, Inc.
2.4.1 AbbVie, Inc.: Total Revenue Forecast to 2028
2.4.2 AbbVie, Inc.: Dermatology Revenue Forecast to 2028
2.4.3 AbbVie, Inc.: Dermatological Drugs Portfolio, 2017
2.4.4 Global Leading Dermatological Drug AbbVie: Humira
2.4.4.1 Humira: Revenue Forecast to 2028
2.4.5 AbbVie, Inc.: Dermatological Drugs Product Pipeline, 2018
2.4.6 AbbVie, Inc.: Recent Developments
2.4.6.1 AbbVie Announces HUMIRA (adalimumab) Patent License with Mylan
2.4.6.2 AbbVie and Calico Announce Extension of Ground-breaking Collaboration
2.4.6.3 AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
2.5 GlaxoSmithKline, plc (GSK)
2.5.1 GlaxoSmithKline, plc (GSK): Total Revenue Forecast to 2028
2.5.2 GlaxoSmithKline, plc (GSK): Dermatology Revenue Forecast to 2028
2.5.3 GlaxoSmithKline, plc. (GSK): Dermatological Drugs Portfolio, 2017
2.5.4 Global Leading Dermatological Drug Glaxosmithkline
2.5.4.1 Valtrex
2.5.4.1.1 Valtrex: Revenue Forecast to 2028
2.5.4.2 Lamisil
2.5.4.2.1 Lamisil: Revenue Forecast to 2028
2.5.4.3 Bactroban
2.5.4.3.1 Bactroban: Revenue Forecast to 2028
2.5.4.4 Dermovate
2.5.4.4.1 Dermovate: Revenue Forecast to 2028
2.5.5 GlaxoSmithKline, plc. (GSK): Dermatological Drugs Product Pipeline, 2018
2.5.6 GlaxoSmithKline, plc. (GSK): Recent Developments
2.5.6.1 GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
2.5.6.2 Business Restructuring Arrangements with Novartis
2.5.6.3 Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
2.6 Pfizer, Inc.
2.6.1 Pfizer, Inc.: Total Revenue Forecast to 2028
2.6.2 Pfizer, Inc.: Dermatology Revenue Forecast to 2028
2.6.3 Pfizer, Inc.: Dermatological Drugs Portfolio, 2018
2.6.4 Global Leading Dermatological Drug Pfizer
2.6.4.1 Zyvox
2.6.4.1.1 Zyvox: Revenue Forecast to 2028
2.6.5 Pfizer, Inc.: Dermatological Drugs Product Pipeline, 2018
2.6.6 Pfizer, Inc.: Recent Developments
2.6.6.1 XELJANZ (Tofacitinib Citrate) receives marketing authorisation in the European Union for active psoriatic arthritis
2.6.6.2 Pfizer to expand venture investing with $600 Million commitment to Pfizer ventures
2.6.6.3 Pfizer receives breakthrough therapy designation from FDA for PF–04965842, an oral JAK1 inhibitor, for the treatment of patients with moderate–to–severe atopic dermatitis
2.7 LEO Pharma A/S
2.7.1 LEO Pharma A/S: Total Revenue Forecast to 2028
2.7.2 LEO Pharma A/S: Dermatology Revenue Forecast to 2028
2.7.3 LEO Pharma A/S: Dermatological Drugs Portfolio, 2018
2.7.4 Global Leading Dermatological Drugs LEO Pharma
2.7.4.1 Protopic
2.7.4.1.1 Protopic: Revenue Forecast to 2028
2.7.5 LEO Pharma A/S: Dermatological Drugs Product Pipeline, 2018
2.7.6 LEO Pharma A/S: Recent Developments
2.7.6.1 LEO Pharma A/S to expand its lead in medical dermatology with acquisition of Bayer’s prescription dermatology unit
2.7.6.2 LEO Pharma A/S begins phase 3 clinical study with tralokinumab in adolescent patients with moderate–to–severe atopic dermatitis
2.7.6.3 LEO Pharma A/S and FibroTx LLC enter partnership to explore non–invasive skin test technology
2.8 Valeant Pharmaceuticals (Bausch Health Companies Inc.)
2.8.1 Valeant Pharmaceuticals: Total Revenue Forecast to 2028
2.8.2 Valeant Pharmaceuticals: Dermatology Revenue Forecast to 2028
2.8.3 Valeant Pharmaceuticals (Bausch Health Companies Inc.): Dermatological Drugs Portfolio, 2018
2.8.4 Global Leading Dermatological Drug Valeant Pharmaceuticals
2.8.4.1 Solodyn
2.8.4.1.1 Solodyn: Revenue Forecast to 2028
2.8.4.2 Ziana
2.8.4.2.1 Ziana: Revenue Forecast to 2028
2.8.5 Valeant Pharmaceuticals (Bausch Health Companies Inc.): Dermatological Drugs Product Pipeline, 2018
2.8.6 Valeant Pharmaceuticals (Bausch Health Companies Inc.): Recent Developments
2.8.6.1 Bausch Health Companies Inc. completes name change
2.8.6.2 Valeant Down as FDA Refuses to Approve Duobrii for Psoriasis
2.8.6.3 Valeant Announces U.S. Launch of SILIQ (brodalumab) Injection
2.9 Almirall S.A.
2.9.1 Almirall S.A.: Total Revenue Forecast to 2028
2.9.2 Almirall S.A.: Dermatology Revenue Forecast to 2028
2.9.3 Almirall S.A.: Dermatological Drugs Portfolio, 2018
2.9.4 Almirall S.A.: Dermatological Drugs Product Pipeline, 2018
2.9.5 Almirall S.A.: Recent Developments
2.9.5.1 Transformational Transaction – Almirall to acquire US medical dermatology portfolio from Allergan
2.9.5.2 Almirall receives positive CHMP opinion for new anti IL23 tildrakizumab for the treatment of patients with moderate–to–severe chronic plaque psoriasis Almirall
2.10 Eli Lilly and Company
2.10.1 Eli Lilly and Company: Total Revenue Forecast to 2028
2.10.2 Eli Lilly and Company: Dermatology Revenue Forecast to 2028
2.10.3 Eli Lilly and Company: Dermatological Drugs Portfolio, 2018
2.10.4 Global Leading Dermatological Drug Eli Lilly: Taltz
2.10.4.1 Taltz: Revenue Forecast to 2028
2.10.5 Eli Lilly and Company: Dermatological Drugs Product Pipeline, 2018
2.10.6 Eli Lilly and Company: Recent Developments
2.10.6.1 Lilly Announces Positive Top–Line Results for Second Phase 3 Study of Taltz (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor–Experienced Patients
2.10.6.2 Lilly Completes Acquisition of ARMO BioSciences
2.11 Mylan N.V.
2.11.1 Mylan N.V.:Total Revenue Forecast to 2028
2.11.2 Mylan N.V.: Dermatology Revenue Forecast to 2028
2.11.3 Mylan N.V.: Dermatological Drugs Portfolio, 2018
2.11.4 Mylan N.V.: Recent Developments
2.11.4.1 Mylan to Bring a Biosimilar of BOTOX to the Market through a Collaboration and License agreement with Revance Therapeutics, Inc.
2.11.4.2 Mylan Completes Acquisition of Renaissance’s Leading Topicals–Focused Specialty and Generics Business
2.11.4.3 Mylan Completes Acquisition of Meda
2.12 Lupin Ltd.
2.12.1 Lupin Ltd.: Total Revenue Forecast to 2028
2.12.2 Lupin Ltd.: Dermatology Revenue Forecast to 2028
2.12.3 Lupin Ltd.: Dermatological Drugs Portfolio, 2018
2.12.4 Lupin Ltd.: Dermatological Drugs Product Pipeline, 2018
2.12.5 Lupin Ltd.: Recent Developments
2.12.5.1 Lupin launches generic Desoximetasone Topical Spray, 0.25% in the US
2.12.5.2 Lupin and Mylan Partner to Commercialize Enbrel (Etanercept) Biosimilar
2.12.5.3 Lupin submits New Drug Application for Etanercept biosimilar in Japan
2.13 Novartis AG
2.13.1 Novartis AG: Total Revenue Forecast to 2028
2.13.2 Novartis AG: Dermatology Revenue Forecast to 2028
2.13.3 Novartis AG: Dermatological Drugs Portfolio, 2018
2.13.4 Global Leading Dermatological Drug Novartis: Cosentyx
2.13.4.1 Cosentyx: Revenue Forecast to 2028
2.13.5 Novartis AG: Dermatological Drugs Product Pipeline, 2018
2.13.6 Novartis AG: Recent Developments
2.13.6.1 Novartis demonstrates commitment to lead immuno–dermatology by in–licensing IL–17C compound for atopic dermatitis
2.13.6.2 Sandoz receives European Commission approval for biosimilar Hyrimoz (adalimumab)
2.13.6.3 Sandoz receives European Commission approval for Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases
2.14 Sanofi
2.14.1 Sanofi: Total Revenue Forecast to 2028
2.14.2 Sanofi: Dermatology Revenue Forecast to 2028
2.14.3 Sanofi: Dermatological Drugs Portfolio, 2018
2.14.4 Sanofi: Recent Developments
2.14.4.1 Sanofi and Advent finalize negotiations for the acquisition of Zentiva
2.14.4.2 Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze–out Procedure
2.14.4.3 Dupixent (dupilumab) showed positive Phase–3 results in adolescents with inadequately controlled moderate–to–severe atopic dermatitis
2.14.4.4 Demand for Dupixent remains strong
2.15 Allergan plc.
2.15.1 Allergan plc.: Total Revenue Forecast to 2028
2.15.2 Allergan plc.: Dermatology Revenue Forecast to 2028
2.15.3 Allergan plc.: Dermatological Drugs Portfolio, 2018
2.15.4 Global Leading Dermatological Drug Allergan
2.15.4.1 Aczone
2.15.4.1.1 Aczone: Revenue Forecast to 2028
2.15.5 Allergan plc.: Dermatological Drugs Product Pipeline, 2018
2.15.6 Allergan plc.: Recent Developments
2.15.6.1 FDA Accepts New Drug Application for Seysara (Sarecycline) for the Treatment of Moderate to Severe Acne
2.15.6.2 ACZONE (dapsone) Gel, 7.5% Recognized with Teen Vogue Acne Award Win
2.15.6.3 Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
2.16 Merck
2.16.1 Merck: Total Revenue Forecast to 2028
2.16.2 Merck: Dermatology Revenue Forecast to 2028
2.16.3 Merck: Dermatological Drugs Portfolio, 2018
2.16.4 Global Leading Dermatological Drug Merck
2.16.4.1 Cubicin
2.16.4.1.1 Cubicin: Revenue Forecast to 2028
2.16.4.2 Elocon
2.16.4.2.1 Elocon: Revenue Forecast to 2028
2.16.5 Merck: Recent Developments
2.16.5.1 Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno–Oncology Pipeline
2.16.5.2 Merck to Acquire Rigontec, RIG–I Therapeutics Pioneer, Advancing Leadership in Immuno–Oncology
2.16.5.3 Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
2.17 Sun Pharmaceutical Industries, Ltd.
2.17.1 Sun Pharmaceutical Industries, Ltd.: Total Revenue Forecast to 2028
2.17.2 Sun Pharmaceutical Industries, Ltd.: Dermatology Revenue Forecast to 2028
2.17.3 Sun Pharmaceutical Industries, Ltd.: Dermatological Drugs Portfolio, 2018
2.17.4 Global Leading Dermatological Drug Sun Pharmaceutical
2.17.4.1 Absorica /Epirus
2.17.4.1.1 Absorica /Epirus: Revenue Forecast to 2028
2.17.5 Sun Pharmaceutical Industries, Ltd.: Recent Developments
2.17.5.1 Sun Pharma Announces U.S. FDA Approval of ILUMYA (tildrakizumab–asmn) for the Treatment of Moderate–to–Severe Plaque Psoriasis
2.17.5.2 Sun Pharma & Samsung BioLogics announce strategic manufacturing tie–up for Tildrakizumab
2.17.5.3 Sun Pharma announces distribution alliance with Mitsubishi Tanabe Pharma Corporation in Japan
2.18 Amgen Inc.
2.18.1 Amgen Inc.: Total Revenue Forecast to 2028
2.18.2 Amgen Inc.: Dermatology Revenue Forecast to 2028
2.18.3 Amgen Inc.: Dermatological Drugs Portfolio, 2018
2.18.4 Global Leading Dermatological Drug Amgen: Enbrel
2.18.4.1 Enbrel: Revenue Forecast to 2028
2.18.5 Amgen Inc.: Dermatological Drugs Product Pipeline, 2018
2.18.6 Amgen Inc.: Recent Developments
2.18.6.1 Amgen Announces Top–Line Results from Phase 3 Study of ABP 710, Biosimilar Candidate to Infliximab
2.18.6.2 Amgen Launches the ENBREL Mini Single–Dose Prefilled Cartridge with AutoTouch Reusable Autoinjector That Is Ergonomically Designed for Patients
2.18.6.3 Amgen and CytomX Therapeutics Announce Strategic Collaboration in Immuno–Oncology
2.19 F. Hoffmann–La Roche Ltd
2.19.1 F. Hoffmann–La Roche Ltd: Total Revenue Forecast to 2028
2.19.2 F. Hoffmann–La Roche Ltd: Dermatology Revenue Forecast to 2028
2.19.3 F. Hoffmann–La Roche Ltd: Dermatological Drugs Portfolio, 2018
2.20 Mayne Pharma
2.20.1 Mayne Pharma: Total Revenue Forecast to 2028
2.20.2 Mayne Pharma: Dermatology Revenue Forecast to 2028
2.20.3 Mayne Pharma: Dermatological Drugs Portfolio, 2018
2.20.4 Global Leading Dermatological Drugs Mayne Pharma
2.20.4.1 Doryx
2.20.4.1.1 Doryx: Revenue Forecast to 2028
2.20.5 Mayne Pharma: Recent Developments
2.20.5.1 Mayne Pharma acquires generic EFUDEX, Complementing US Dermatology Portfolio
2.20.5.2 Mayne Pharma announces FDA approval and immediate launch of Doxycycline Hyclate IR tablets, first generic to Acticlate
2.20.5.3 Mayne Pharma launches Fabior and Sorilux in the UNITED STATES
2.21 Concert Pharmaceuticals, Inc.
2.21.1 Concert Pharmaceuticals, Inc.: Total Revenue Forecast to 2028
2.21.2 Concert Pharmaceuticals, Inc.: Dermatology Revenue Forecast to 2028
2.21.3 Concert Pharmaceuticals, Inc.: Recent Developments
2.21.3.1 Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement
2.21.3.2 Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium–Modified Compounds
2.22 Novan, Inc.
2.22.1 Novan, Inc.: Total Revenue Forecast to 2028
2.22.2 Novan, Inc.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
2.22.3 Novan, Inc.: Dermatological Drugs Product Pipeline, 2018
2.22.4 Novan, Inc.: Recent Developments
2.22.4.1 Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
2.22.4.2 Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
2.22.4.3 Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
2.23 Bayer AG
2.23.1 Bayer AG: Total Revenue Forecast to 2028
2.23.2 Bayer AG: Dermatology Revenue Forecast to 2028
2.23.3 Bayer AG: Dermatological Drugs Portfolio, 2018
2.23.4 Global Leading Dermatological Drugs Bayer
2.23.4.1 Canesten
2.23.4.1.1 Canesten: Revenue Forecast to 2028
2.23.4.2 Bepanthen/Bepanthol
2.23.4.2.1 Bepanthen/ Bepanthol: Revenue Forecast to 2028
2.23.5 Bayer AG: Recent Developments
2.23.5.1 Bayer hones its brand profile
2.23.5.2 Bayer combines pharmaceutical research and development unit
2.24 Astellas Pharma Inc.
2.24.1 Astellas Pharma Inc.: Total Revenue Forecast to 2028
2.24.2 Astellas Pharma Inc.: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
2.24.3 Astellas Pharma Inc.: Dermatological Drugs Portfolio, 2018
2.24.4 Astellas Pharma Inc.: Recent Developments
2.24.4.1 Astellas Acquires Universal Cells, Inc.
2.25 Pierre Fabre, S.A.
2.24.1 Pierre Fabre, S.A.: Total Revenue Forecast to 2028
2.24.2 Pierre Fabre, S.A.: Dermatology Revenue Forecast to 2028
2.25.3 Pierre Fabre, S.A.: Dermatological Drugs Portfolio, 2018
2.25.4 Pierre Fabre, S.A.: Recent Developments
2.25.4.1 Pierre Fabre Pharmaceuticals acquires promising assets from Igenica Biotherapeutics in the field of immuno–oncology
2.25.4.2 PIERRE FABRE signs a partnership with biotech company SETUBIO as part of the Nature Open Library program
2.25.4.3 Pierre Fabre and Hill Dermaceuticals, Inc. announce a strategic commercial partnership for TOLAK (fluorouracil) Cream 4% in the USA and beyond

3. Conclusion

Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 2.1 Leading Dermatological Drug Manufacturers: Total Company Revenue ($bn), 2017
Table 2.2 Leading Dermatological Drug Manufacturers: Dermatology Segment Revenue ($bn), 2017
Table 2.3 Galderma: Company Overview, 2017
Table 2.4 Galderma (Nestle Skin Health S.A.): Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.5 Galderma (Nestle Skin Health S.A.): Dermatology Revenue Forecast: (US$ bn), AGR (%), CAGR (%), 2018–2028
Table 2.6 Epiduo: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.7 Differin: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.8 Johnson & Johnson: Company Overview, 2017
Table 2.9 Johnson & Johnson: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.10 Johnson & Johnson: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.11 Stelara: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.12 Remicade: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.13 AbbVie, Inc.: Company Overview, 2017
Table 2.14 AbbVie, Inc.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.15 AbbVie, Inc.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.16 Humira: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.17 AbbVie Inc., Dermatological Drug Pipeline, 2018
Table 2.18 GlaxoSmithKline, plc (GSK): Company Overview, 2017
Table 2.19 GlaxoSmithKline, plc (GSK): Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.20 GlaxoSmithKline, plc (GSK): Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.21 Valtrex: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.22 Lamisil: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.23 Bactroban: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.24 Dermovate: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.25 GlaxoSmithKline, plc., dermatological drug pipeline, 2018
Table 2.26 Pfizer, Inc.: Company Overview, 2017
Table 2.27 Pfizer, Inc.: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.28 Pfizer, Inc.: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.29 Zyvox: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.30 Pfizer, Inc.: Dermatological Drug Pipeline, 2018
Table 2.31 LEO Pharma A/S: Company Overview, 2017
Table 2.32 LEO Pharma A/S: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.33 LEO Pharma A/S: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.34 Protopic: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.35 LeoPharmaA/S: Dermatological Drug Pipeline, 2018
Table 2.36 Valeant Pharmaceuticals (Bausch Health Companies Inc.): Company Overview, 2017
Table 2.37 Valeant Pharmaceuticals: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.38 Valeant Pharmaceuticals: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018 – 2028
Table 2.39 Solodyn: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.40 Ziana: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.41 Valeant Pharmaceuticals: Dermatological Drug Pipeline, 2018
Table 2.42 Almirall S.A.: Company Overview, 2017
Table 2.43 Almirall S.A.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018 – 2028
Table 2.44 Almirall S.A.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.45 Almirall S.A.: Dermatological Drug Pipeline, 2018
Table 2.46 Eli Lilly and Company: Company Overview, 2017
Table 2.47 Eli Lilly and Company: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.48 Eli Lilly and Company: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.49 Taltz: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.50 Eli Lilly and Company: Dermatological Drug Pipeline, 2018
Table 2.51 Mylan N.V.: Company Overview, 2017
Table 2.52 Mylan N.V.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.53 Mylan N.V.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.54 Lupin Ltd.: Company Overview, 2017
Table 2.55 Lupin Ltd.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.56 Lupin Ltd.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.57 Lupin Ltd: Dermatological Drug Pipeline, 2018
Table 2.58 Novartis AG: Company Overview, 2017
Table 2.59 Novartis AG: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.60 Novartis AG: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.61 Cosentyx: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.62 Novartis AG: Dermatological Drug Pipeline, 2018
Table 2.63 Sanofi: Company Overview, 2017
Table 2.64 Sanofi: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.65 Sanofi: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.66 Allergan plc.: Company Overview, 2017
Table 2.67 Allergan plc.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.68 Allergan plc.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.69 Aczone: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.70 Allergan, plc: Dermatological Drug Pipeline, 2018
Table 2.71 Merck: Company Overview, 2017
Table 2.72 Merck: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.73 Merck: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.74 Cubicin: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.75 Elocon: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.76 Sun Pharmaceutical Industries, Ltd.: Company Overview, 2017
Table 2.77 Sun Pharmaceutical Industries, Ltd.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.78 Sun Pharmaceutical Industries, Ltd.: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.79 Absorica /Epirus: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.80 Amgen Inc.: Company Overview, 2017
Table 2.81 Amgen Inc.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.82 Amgen Inc.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.83 Enbrel: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.84 Amgen, Inc.: Dermatological Drug Pipeline, 2018
Table 2.85 F. Hoffmann–La Roche Ltd: Company Overview, 2017
Table 2.86 F. Hoffmann–La Roche Ltd: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.87 F. Hoffmann–La Roche Ltd: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.88 Mayne Pharma: Company Overview, 2017
Table 2.89 Mayne Pharma: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.90 Mayne Pharma: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.91 Doryx: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.92 Concert Pharmaceuticals, Inc.: Company Overview, 2017
Table 2.93 Concert Pharmaceuticals, Inc.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.94 Concert Pharmaceuticals, Inc.: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.95 Novan, Inc.: Company Overview, 2017
Table 2.96 Novan, Inc.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.97 Novan, Inc.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.98 Novan, Inc.: Dermatological Drug Pipeline, 2018
Table 2.99 Bayer AG: Company Overview, 2017
Table 2.100 Bayer AG: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.101 Bayer AG: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.102 Canesten: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.103 Bepanthen/ Bepanthol: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.104 Astellas Pharma Inc.: Company Overview, 2017
Table 2.105 Astellas Pharma Inc.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.106 Astellas Pharma Inc.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018–2028
Table 2.107 Pierre Fabre, S.A.: Company Overview, 2017
Table 2.108 Pierre Fabre, S.A.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018–2028

List of Figures
Figure 2.1 Galderma: Total Revenue Forecast ($bn), 2018-2028
Figure 2.2 Galderma: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.3 Epiduo: Revenue Forecast ($bn), 2018-2028
Figure 2.4 Differin: Revenue Forecast ($bn), 2018-2028
Figure 2.5 Johnson & Johnson: Total Revenue Forecast ($bn), 2018-2028
Figure 2.6 Johnson & Johnson: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.7 Stelara: Revenue Forecast ($bn), 2018-2028
Figure 2.8 Remicade: Revenue Forecast ($bn), 2018-2028
Figure 2.9 AbbVie, Inc.: Revenue Forecast ($bn), 2018-2028
Figure 2.10 AbbVie, Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.11 Humira: Revenue Forecast ($bn), 2018-2028
Figure 2.12 GlaxoSmithKline, plc (GSK): Total Revenue Forecast ($bn), 2018-2028
Figure 2.13 GlaxoSmithKline, plc (GSK): Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.14 Valtrex: Revenue Forecast ($bn), 2018-2028
Figure 2.15 Lamisil: Revenue Forecast ($bn), 2018-2028
Figure 2.16 Bactroban: Revenue Forecast ($bn), 2018-2028
Figure 2.17 Dermovate: Revenue Forecast ($bn), 2018-2028
Figure 2.18 Pfizer, Inc.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.19 Pfizer, Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.20 Zyvox Revenue Forecast ($bn), 2018-2028
Figure 2.21 LEO Pharma A/S: Total Revenue Forecast ($bn), 2018-2028
Figure 2.22 LEO Pharma A/S: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.23 Protopic: Revenue Forecast ($bn), 2018-2028
Figure 2.24 Valeant Pharmaceuticals: Total Revenue Forecast ($bn), 2018-2028
Figure 2.25 Valeant Pharmaceuticals: Dermatology Revenue Forecast ($bn), 2018 - 2028
Figure 2.26 Solodyn: Revenue Forecast ($bn), 2018-2028
Figure 2.27 Ziana: Revenue Forecast ($bn), 2018-2028
Figure 2.28 Almirall S.A.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.29 Almirall S.A.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.30 Eli Lilly and Company: Total Revenue Forecast ($bn), 2018-2028
Figure 2.31 Eli Lilly and Company: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.32 Taltz: Revenue Forecast ($bn), 2018-2028
Figure 2.33 Mylan N.V.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.34 Mylan N.V.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.35 Lupin Ltd.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.36 Lupin Ltd.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.37 Novartis AG: Total Revenue Forecast ($bn), 2018-2028
Figure 2.38 Novartis AG: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.39 Cosentyx: Revenue Forecast ($bn), 2018-2028
Figure 2.40 Sanofi: Total Revenue Forecast ($bn), 2018-2028
Figure 2.41 Sanofi: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.42 Allergan plc.: Total Revenue Forecast (US$ bn), 2018-2028
Figure 2.43 Allergan plc.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.44 Aczone: Revenue Forecast ($bn), 2018-2028
Figure 2.45 Merck: Total Revenue Forecast ($bn), 2018-2028
Figure 2.46 Merck: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.47 Cubicin: Revenue Forecast ($bn), 2018-2028
Figure 2.48 Elocon: Revenue Forecast ($bn), 2018-2028
Figure 2.49 Sun Pharmaceutical Industries, Ltd.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.50 Sun Pharmaceutical Industries, Ltd.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.51 Absorica /Epirus: Revenue Forecast ($bn), 2018-2028
Figure 2.52 Amgen Inc.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.53 Amgen Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.54 Enbrel Revenue Forecast: ($bn), 2018-2028
Figure 2.55 F. Hoffmann-La Roche Ltd: Total Revenue Forecast ($bn), 2018-2028
Figure 2.56 F. Hoffmann-La Roche Ltd: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.57 Mayne Pharma: Total Revenue Forecast ($bn), 2018-2028
Figure 2.58 Mayne Pharma: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.59 Doryx: Revenue Forecast ($bn), 2018-2028
Figure 2.60 Concert Pharmaceuticals, Inc.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.61 Concert Pharmaceuticals, Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.62 Novan, Inc.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.63 Novan, Inc.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.64 Bayer AG: Total Revenue Forecast ($bn), 2018-2028
Figure 2.65 Bayer AG: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.66 Canesten: Revenue Forecast ($bn), 2018-2028
Figure 2.67 Bepanthen/ Bepanthol: Revenue Forecast ($bn), 2018-2028
Figure 2.68 Astellas Pharma Inc.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.69 Astellas Pharma Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
Figure 2.70 Pierre Fabre, S.A.: Total Revenue Forecast ($bn), 2018-2028
Figure 2.71 Pierre Fabre, S.A.: Dermatology Revenue Forecast ($bn), 2018-2028

★調査レポート[皮膚科用医薬品製造のトップ25社2019] ( Top 25 Dermatological Drugs Manufacturers 2019 / VGN906172) 販売に関する免責事項
[皮膚科用医薬品製造のトップ25社2019] ( Top 25 Dermatological Drugs Manufacturers 2019 / VGN906172) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆